Division of Amgen Inc.
Latest From Micromet Inc.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
Amgen oncology development VP Greg Friberg talked to Scrip about the company's rapidly growing oncology portfolio. "This is our renaissance," he said.
TCR2 Therapeutics raised a $125m Series B round to take two T-cell receptor (TCR)-based therapies into the clinic for solid tumors. The company's technology platform overcomes HLA-matching issues to make TCR-based treatments available to more patients.
- Large Molecule
- Therapeutic Areas
- Micromet AG
- North America
- Parent & Subsidiaries
- Amgen Inc.
- Senior Management
Patrick A Baeuerle, PhD, SVP, CSO
Jan Fagerberg, MD, PhD, SVP, CMO
Joseph Lobacki, Chief Commercial Officer
- Contact Info
Phone: (240) 752-1420
9201 Corp. Blvd.
Rockville, MD 20850
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.